The Biomedical Advanced Research and Development Authority quietly suspended funding of COVID-19 therapeutic work on 5 May, a move that even if temporary could lead drug companies, particularly smaller biotech firms, to abandon the space, experts caution.
The move is reminiscent of mistakes made in past pandemics, where research was stopped mid-course, leaving society less prepared the...